Systemic treatment of renal cell cancer: A comprehensive review

Slides:

Advertisements

Similar presentations

Waging War on Cancer with the Sword of Immunity Cell Volume 158, Issue 2, (July 2014) DOI: /j.cell Copyright © 2014 Terms and Conditions.

Advertisements

Irreplaceability of Neuronal Ensembles after Memory Allocation Naoki Matsuo Cell Reports Volume 11, Issue 3, Pages (April 2015) DOI: /j.celrep

Cancer Metabolism Cell Volume 148, Issue 3, (February 2012) DOI: /j.cell Copyright © 2012 Terms and Conditions Terms and Conditions.

The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes Tae-Min Kim, Peter W. Laird, Peter J. Park Cell Volume 155, Issue.

The Good Fat Cell Volume 147, Issue 7, (December 2011) DOI: /j.cell Copyright © 2011 Terms and Conditions Terms and Conditions.

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Differential drug responses of circulating tumor cells within patient blood Andrew D. Hughes, Jocelyn R. Marshall, Eric Keller, John D. Powderly, Bryan.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP CHEST

Juan W. Valle, Sandrine Faivre, Richard A

Stem cell-based therapy for malignant glioma

GEIS guidelines for gastrointestinal sarcomas (GIST)

Managing Cancer Pain: Basic Principles and Invasive Treatments

Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies A. Vogel, R.D. Hofheinz, S. Kubicka, D. Arnold

Triple negative breast cancer in Asia: An insider’s view

Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials Pippa Newell, Augusto Villanueva, Josep M. Llovet

IRS-1: Auditing the effectiveness of mTOR inhibitors

Accelerating drug discovery: Open source cancer cell biology?

Personalizing Therapy for Colorectal Cancer

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Pain in cancer survivors; filling in the gaps

A Flt3L Encounter: mTOR Signaling in Dendritic Cells

Making Sense of HDAC2 Mutations in Colon Cancer

Personalizing Therapy for Colorectal Cancer

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

Volume 50, Issue 5, Pages (November 2006)

In This Issue Cell Volume 158, Issue 5, (August 2014)

PICS-ure This: Prosenescence Therapy?

Foxo1 and Foxo3 help Foxp3 Immunity

Apoptosis-targeted therapies for cancer

Volume 22, Issue 6, Pages (December 2012)

Inhibition of mammalian target of rapamycin: Two goals with one shot?

Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills Cancer Cell

Volume 26, Issue 2, Pages (February 2018)

Lip edema Journal of the American Academy of Dermatology

Harald P. Hoensch, Reinhard Oertel Clinical Nutrition Experimental

IRS-1: Auditing the effectiveness of mTOR inhibitors

Volume 152, Issue 1, (January 2013)

Sergio Bracarda European Urology Supplements

Acupuncture for treatment of therapy-resistant post-dural puncture headache: a retrospective case series J. Dietzel, T. Witstruck, S. Adler, T.I. Usichenko

Barrie R. Cassileth, PhD, Andrew J. Vickers, PhD

Volume 139, Issue 5, (November 2009)

Volume 130, Issue 6, (September 2007)

Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer Thomas Winder, Heinz–Josef.

News & Notes Journal of Allergy and Clinical Immunology

847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach Molecular.

Volume 143, Issue 6, (December 2010)

Apoptosis-targeted therapies for cancer

mTOR Regulation by JNK: Rescuing the Starving Intestinal Cancer Cell?

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Shorter duration of antibiotic treatment for acute bacteraemic cholangitis with successful biliary drainage: a retrospective cohort study A. Doi, T.

Organization news Archives of Physical Medicine and Rehabilitation

In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)

Joaquim Bellmunt European Urology Supplements

A Meta-Analysis of the Relationship Between Response Expectancies and Cancer Treatment-Related Side Effects Stephanie J. Sohl, PhD, Julie B. Schnur,

C. Price, J. Lee, A.M. Taylor, A.P. Baranowski

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

J Lee, S Gupta, C Price, A.P. Baranowski

Is complement a target for therapy in renal disease?

Tailor Made Protein Synthesis for HSCs

Jan Roigas European Urology Supplements

Volume 163, Issue 4, (November 2015)

Managing Cancer Pain: Basic Principles and Invasive Treatments

Volume 163, Issue 2, (October 2015)

Volume 51, Issue 5, Pages (May 2007)

Volume 134, Issue 6, (September 2008)

In This Issue Cell Volume 145, Issue 3, (April 2011)

Volume 148, Issue 1, (January 2012)

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Volume 3, Issue 5, Pages (November 2017)

Presentation transcript:

Systemic treatment of renal cell cancer: A comprehensive review Amparo Sánchez-Gastaldo, Emmanuelle Kempf, Aránzazu González del Alba, Ignacio Duran Cancer Treatment Reviews Volume 60, Pages 77-89 (November 2017) DOI: 10.1016/j.ctrv.2017.08.010 Copyright © 2017 The Author(s) Terms and Conditions

Fig. 1 Angiogenesis pathway and targeted therapies in RCC. Cancer Treatment Reviews 2017 60, 77-89DOI: (10.1016/j.ctrv.2017.08.010) Copyright © 2017 The Author(s) Terms and Conditions

Fig. 2 PI3K-AKT-mTOR pathway and targeted therapies in RCC. Cancer Treatment Reviews 2017 60, 77-89DOI: (10.1016/j.ctrv.2017.08.010) Copyright © 2017 The Author(s) Terms and Conditions

Fig. 3 MET pathway and targeted therapies in RCC. Cancer Treatment Reviews 2017 60, 77-89DOI: (10.1016/j.ctrv.2017.08.010) Copyright © 2017 The Author(s) Terms and Conditions